instruction:
Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.
question:
With the recent introduction of inhibitors of mammalian target of rapamycin (mTOR) in oncology, distinct cutaneous and oral adverse events have been identified. In fact, stomatitis and rash are documented as the most frequent and potentially dose-limiting side effects. Clinically, mTOR inhibitor-associated stomatitis (mIAS) more closely resembles aphthous stomatitis than oral mucositis due to conventional anticancer therapies. While most cases of mIAS are mild to moderate and self-limiting, more severe and persistent mIAS can become a dose-limiting toxicity. Small ulcerations may cause significant pain and mucosal sensitivity may occur in the absence of clinical changes. Use of clinical assessment tools that are primarily driven by ulceration size may underestimate mIAS, and assessment should include patient-reported outcomes. This article provides an up-to-date review of the clinical presentation, terminology, pathogenesis, assessment and management of mIAS and other mTOR inhibitor-associated oral adverse events. In addition, areas of future research are considered.
answer:
What does mTOR stands for?


question:
Chronic myeloid leukemia (CML) is a progressive and often fatal myeloproliferative neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the Philadelphia chromosome (Ph), which results in the synthesis of the breakpoint cluster region-Abelson murine leukemia (BCR-ABL) fusion oncoprotein, a constitutively active tyrosine kinase. The introduction of imatinib, a tyrosine kinase inhibitor (TKI) that is specific for BCR-ABL, was a major breakthrough in CML therapy. Although most patients respond to first-line imatinib therapy, some experience loss of response (resistance) or require treatment discontinuation because of toxicity (intolerance). For patients with CML, failure on standard-dose imatinib therapy (400 mg daily), imatinib dose escalation (600-800 mg daily) is a second-line option. However, high-dose imatinib is not an appropriate approach for patients who experience drug toxicity, and there remain questions over the durability of responses achieved with this strategy. Alternative second-line options include the TKIs dasatinib and nilotinib. A substantial amount of long-term data for these agents is available. Although both are potent and specific BCR-ABL TKIs, dasatinib and nilotinib exhibit unique pharmacologic profiles and response patterns relative to different patient characteristics, such as disease stage and BCR-ABL mutation status. To optimize therapeutic benefit, clinicians should select treatment based on each patient's historic response, adverse-event tolerance, and risk factors.
answer:
What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?


question:
An experiment was carried out at British school into the performance of new pupils. At the start of the year, the pupils were each given a _ , ranging from "excellent prospect" to "unlikely to do well". These were totally untrue ratings and did not reflect how well the pupils had previously performed. However, these ratings were given to the teachers. At the end of the year, the experimenters compared the pupils' performance with the ratings. Despite their real abilities, there was an astonishingly high connection between performance and ratings. It seems that people perform as well as we expect them to. The Self-fulfilling Effect is also known as the Pygmalion Effect. This comes from an old Greek story. The story was also the basis of George Bernard Shaw's play "Pygmalion", later turned into the musical "My Fair Lady". In Shaw's play, Professor Henry Higgins claims he can turn a Cockney flower girl, Eliza Doolittle into a duchess. But, as Eliza herself points out to Higgins' friend Pickering, it isn't what she learns or does that determines whether she will become a duchess, but how she's treated. The implication of the Pygmalion Effect for leaders and managers is massive. It means that the performance of your team depends less on them than it does on you. The performance you get from people is no more or less than what you expect, which means you must always expect the best. As Goethe said, "Treat a man as he is and he will remain as he is. Treat a man as he can and should be and he will become as he can and should be."
answer:

What's the passage mainly about?